TACE联合索拉非尼治疗不能手术切除肝细胞癌介入治疗间隔时间的分析

TACE combined with sorafenib for inoperable hepatocellular carcinoma: analysis of treatment interval

目的观察经动脉化疗栓塞术(TACE)联合索拉非尼治疗不能手术切除肝细胞癌(HCC)的临床疗效,评价联合治疗间隔时间对于患者TACE治疗的影响。方法 50例不能手术切除的肝细胞癌患者,于2008年7月—2011年5月接受TACE联合索拉非尼治疗,比较患者联合治疗前后TACE治疗间隔时间。结果截至2011年12月31日,50例患者中位随访时间310 d,联合治疗后TACE治疗平均间隔时间为112 d,最长间隔时间648 d,联合治疗前患者TACE治疗平均间隔时间69 d。结论 TACE联合索拉非尼治疗可以显著延长患者TACE治疗间隔时间,使患者得到更多的生存获益。

Objective To investigate the clinical efficacy of transarterial chemoembolization （TACE） combined with sorafenib for the treatment of inoperable hepatocellular carcinoma （HCC）, and to discuss the influence of treatment interval on the survival time. Methods During the period from July 2008 to May 2011 at authors’ hospital, a total of 50 patients with inoperable HCC were treated with TACE together with sorafenib. The treatment intervals between each TACE procedure were recorded. The results were analyzed. Results Up to Dec. 31, 2011, the median follow-up time of the 50 patients was 310 days. The mean interval between TACE treatments was 69 days before the combination treatment was employed , while the mean interval was 112 days after the combination treatment started , and the longest interval was 648 days. Conclusion Combination treatment TACE with sorafenib can remarkably prolong the treatment interval in patients with inoperable HCC, thus the patient can get more survival benefits.